title: Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting.
authors: N
authors: N
authors: Kumarasamy
authors: Kartik K
authors: KK
authors: Venkatesh
authors: Bella
authors: B
authors: Devaleenal
authors: Vidhya
authors: V
authors: Palanivel
authors: Anitha J
authors: AJ
authors: Cecelia
authors: Sundaram
authors: S
authors: Muthu
authors: Tokugha
authors: T
authors: Yepthomi
authors: Kenneth H
authors: KH
authors: Mayer
authors: Timothy
authors: T
authors: Flanigan
mesh_terms: D000328:Adult; D000480:Alkynes; D023241:Antiretroviral Therapy, Highly Active; D048588:Benzoxazines / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D056486:Chemical and Drug Induced Liver Injury; D003365:Costs and Cost Analysis; D003521:Cyclopropanes; D005260:Female; D006678:HIV; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics / Q000276:immunology; D006801:Humans; D007194:India; D008099:Liver / Q000503:physiopathology; D008107:Liver Diseases / Q000503:physiopathology; D008297:Male; D019829:Nevirapine / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D011446:Prospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; C098320:efavirenz